News
Patients with mental illness a priority for COVID vaccine, experts say
November 12, 2020
Even without factoring COVID-19 into the mix, individuals with severe mental illness have a two- to threefold higher mortality rate than the general population.
![1]()
News
Treatments for COVID-19: Update for hospitalists
November 12, 2020
Currently, there is no clinically proven specific antiviral treatment for COVID-19.
News
Search for a snakebite drug might lead to a COVID treatment, too
November 11, 2020
Varespladib has proven itself in in-vitro studies, has effectively saved mice and pigs dosed with venom, and shows a positive effect on acute respiratory distress syndrome.
News
Moral distress: COVID-19 shortages prompt tough decisions at bedside
November 11, 2020
Many hospital crisis capacity plans were too general to address all the specific challenges arising during the pandemic.
![1]()
News
FDA grants emergency use authorization to Lilly’s antibody COVID-19 therapy
November 10, 2020
“We have supplies to distribute now. Product distribution will begin this week.”
News
Great Barrington coauthor backs off strict reliance on herd immunity
November 10, 2020
The Great Barrington approach advocates isolation and protection of people who are most vulnerable to COVID-19 while avoiding what they characterize as lockdowns.
News
Hospitals poised to launch first COVID-19 vaccines in clinicians
November 10, 2020
Hospitals have a sophisticated infrastructure to deliver flu vaccines, but that framework doesn’t align with likely scenarios for a SARS-CoV-2 vaccine.
![1]()
News
United States adds nearly 74,000 more children with COVID-19
November 10, 2020
New weekly high in pediatric cases seen for the second consecutive week.
News
Whales, seals, and dolphins: Will SARS-CoV-2–contaminated wastewater prove a killer?
November 10, 2020
Environmental pollution during the COVID-19 pandemic puts dolphins, whales, seals, and otters among the sea mammals at risk.
News
Pfizer vaccine data show 90% efficacy in early results
November 9, 2020
BTN162b2, a messenger RNA–based vaccine candidate that requires two doses, is being developed by Pfizer and BioNTech SE.
